US panel to review Lux Biosciences' uveitis treatment voclosporin
This article was originally published in Scrip
Executive Summary
The US FDA's dermatologic and ophthalmic drugs advisory panel will meet on 28 June to review Lux Biosciences' immunosuppressant Luveniq (oral voclosporin; formerly LX211) for the treatment of non-infectious uveitis involving the posterior or intermediate segments of the eye.